Purchase this article with an account.
Nabil Jabbour, Frank Ruda, Adel Wahba; Treatment of Macular Edema (secondary to vein occlusion) with Dexamethasone Implant (Ozurdex). Invest. Ophthalmol. Vis. Sci. 2013;54(15):254.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the response & complications of treating macular edema (ME) secondary to vein occlusion (VO) with Ozurdex (IVO), especially in cases not responding to anti-VEGF treatment.
40 eyes were treated with IVO & followed up for 6-24 months (an average of 12M) with additional treatment PRN. 7 (18%) were primary and 33 eyes (82%) were “rescue” (non-responders to Avastin and/or Lucentis).
Overall, 94% showed full initial regression on OCT lasting an average of 4.2 months with 2 lines of improvement. 59% improved (14.2 letters), 10% worsened (6.7 letters) and 31% remained stable. 19% showed elevated intraocular pressure; all successfully treated with drops. The primary treatment group showed 100% regression with 13.3 letters of improvement; 86% improved and 14% remained stable. Only 20 (50%) required more than one treatment of IVO (average of 1.6 treatments per year). CRVO showed better anatomic & visual response than BRVO.
IVO seems to be an effective & safe treatment for VO, especially central. Many eyes that showed initial or latent “resistance” to anti-VEGF showed good response to IVO, making IVO a good “rescue” option for ME secondary to vein occlusion.
This PDF is available to Subscribers Only